Eric C Breinlinger

This inventor holds 12 USPTO granted patents and 10 published patent applications and 1 EPO patent. Top assignees: Abbvie Inc., Abbott Laboratories Corporation. Active years: 2010-2019.

USPTO Granted Patents = 12 (Patent Applications = 10)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 10)

Average Co-Inventor Count = 10.7

ph-index = 2

Forward Citations = 94(Granted Patents)

Company Filing History:

Abbott Laboratories Corporation

patents

Years Active: 2010-2019

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10508113 - Inhibitors of tyrosine kinase 2 mediated signaling (2019-12-17),

2. 10273238 - Indazolones as modulators of TNF signaling (2019-04-30),

3. 10266532 - Tricyclic modulators of TNF signaling (2019-04-23),

4. 10160748 - Indazolones as modulators of tnf signaling (2018-12-25),

5. 10106501 - Nuclear receptor modulators (2018-10-23),

6. 9879016 - Indazolones as modulators of TNF signaling (2018-01-30),

7. 9856253 - Tricyclic modulators of TNF signaling (2018-01-02),

8. 9115151 - Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof (2015-08-25),

9. 9029409 - Isoxazolines as therapeutic agents (2015-05-12),

10. 8785639 - Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof (2014-07-22),

11. 8217027 - Sphingosine-1-phosphate receptor agonist and antagonist compounds (2012-07-10),

12. 7834039 - Oxadiazole compounds (2010-11-16),

Title: The Innovative Contributions of Eric C Breinlinger

Introduction

Eric C Breinlinger is a notable inventor based in Charlton, MA (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 12 patents to his name, Breinlinger has made strides in developing compounds that target critical biological pathways.

Latest Patents

Among his latest patents is a groundbreaking work on "Inhibitors of tyrosine kinase 2 mediated signaling." This patent discloses compounds of Formula (I) and their pharmaceutically acceptable salts, which are designed to modulate signaling pathways. Another significant patent is focused on "Indazolones as modulators of TNF signaling." This disclosure provides compounds of Formula (I), including pro-drugs and biologically active metabolites, which are useful for treating immunological and oncological conditions.

Career Highlights

Breinlinger has had a distinguished career, working with prominent companies such as AbbVie Inc. and Abbott Laboratories Corporation. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.

Collaborations

Throughout his career, Breinlinger has collaborated with esteemed colleagues, including Michael M Friedman and Maria A Argiriadi. These partnerships have fostered innovation and enhanced the impact of his research.

Conclusion

Eric C Breinlinger exemplifies the spirit of innovation in the pharmaceutical industry through his patents and collaborations. His work continues to influence the development of new treatments for various medical conditions.